Has Samuel Tsappidi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $53,709 in general payments to Samuel Tsappidi, MD across 156 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samuel Tsappidi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samuel Tsappidi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samuel Tsappidi, MD

Neurocritical Care · Augusta, GANPI 1255537122

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,350 of the $53,709 with a category attached, or 69.5%. Microvention, Inc. accounts for 66.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $33,763, more than ten times the $122 reported in 2019.

$53,709in general payments, 2019–2025

Across 156 payments — averaging $344.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Microvention, Inc.$36K
Stryker$10K
Johnson & Johnson$2K
Medtronic$1K
Penumbra, Inc.$1K
Imperative Care, Inc$967
plus $3K from 15 others

$10,318in research payments, 2019–2025

Across 4 payments — averaging $2579.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Microvention, Inc.$10K

What the payments were for

Consulting fees$37,35070%
Travel & lodging$5751%
Food & beverage$15,78429%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Microvention, Inc.	48	$35,879
Stryker	29	$9,715
Johnson & Johnson	19	$1,846
Medtronic	13	$1,293
Penumbra, Inc.	9	$1,058
Imperative Care, Inc	8	$967
Rapid Medical Ltd	6	$571
Balt USA, LLC	2	$553
Scientia Vascular	2	$454
Siemens Medical Solutions USA, Inc.	2	$274
Maduro Medical, Inc.	1	$238
Silk Road Medical, Inc.	2	$213
Boston Scientific	2	$176
Sirtex Medical Inc	2	$148
Biosense Webster, Inc.	1	$117
Chiesi USA, Inc.	3	$52
Terumo Medical Corporation	2	$50
Genentech USA, Inc.	2	$37
Contego Medical, Inc	1	$27
Qapel Medical Inc	1	$23
Biocompatibles, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

STENT$33,148
WEB Aneurysm Embolization System$13,228
NA$5,880
AXS VECTA 71$3,920
NSE - TPS BURSTSP ELITE BURS$2,940
BROADWAY 8$2,450
SURPASS EVOLVE$1,015
TGS$980
TRUFILL$844
Pipeline$728
Embotrap$611
Optima Coil System$553
TIGERTRIEVER 17 REVASCULARIZATION DEVICE$546
COMANECI 17$546
Penumbra System$461
ZOOM 88-T LARGE DISTAL PLATFORM$392
SOFIA 6F-131CM STR$375
ERIC RETRIEVAL DEVICE$300
ENROUTE Transcarotid Neuroprotection System$287
Socrates 38$243

How this compares

Too few neurocritical care providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$140,098

Medicare patients

103

Services billed

613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BrilintaTicagrelor	28	$16,832

Paid to pharmacies, not to this prescriber.

Other neurocritical care in Augusta

Manan ShahAugusta$3K
Klepper GarciaAugusta$997
Manjunath MarkandayaGainesville$12K
Anand SarmaAtlanta$2K
Christopher HornMarietta$897
Andres RuizGainesville$486
Anantha VellipuramAtlanta$361
Joao Mc-Oneil PlancherMarietta$314
Starane ShepherdAtlanta$268
Muthu BhaskaranAtlanta$235

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →